uniQure N.V. (NASDAQ:QURE) issued its earnings results on Tuesday. The biotechnology company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.05, MarketWatch Earnings reports. The company had revenue of $4.94 million for the quarter, compared to analysts’ expectations of $2.92 million. uniQure N.V. had a negative return on equity of 103.26% and a negative net margin of 223.38%.

In related news, insider Harald Petry sold 65,930 shares of the company’s stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $6.01, for a total transaction of $396,239.30. Following the sale, the insider now directly owns 155 shares of the company’s stock, valued at approximately $931.55. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders have sold 173,460 shares of company stock worth $1,042,986. 0.64% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/uniqure-n-v-nasdaqqure-releases-earnings-results-misses-estimates-by-0-05-eps.html.

A number of brokerages have recently commented on QURE. Zacks Investment Research raised shares of uniQure N.V. from a “sell” rating to a “hold” rating in a research report on Wednesday. Oppenheimer Holdings, Inc. set a $17.00 target price on shares of uniQure N.V. and gave the stock a “buy” rating in a research report on Tuesday, May 16th. ValuEngine lowered shares of uniQure N.V. from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Jefferies Group LLC reaffirmed a “hold” rating and set a $8.00 target price on shares of uniQure N.V. in a research report on Wednesday, April 12th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of uniQure N.V. in a research report on Wednesday, May 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $14.61.

uniQure N.V. Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Earnings History for uniQure N.V. (NASDAQ:QURE)

Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.